Trial Outcomes & Findings for Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Propranolol/Carvedilol Versus Atenolol/Bisoprolol/Sotalol (NCT NCT05794997)
NCT ID: NCT05794997
Last Updated: 2025-11-10
Results Overview
Time to dementia onset, i.e., Alzheimer's disease, vascular dementia, senile, presenile, or unspecified dementia, or dementia in other diseases classified elsewhere. Please refer to uploaded protocol for full definition due to size limitations.
Recruitment status
COMPLETED
Target enrollment
817337 participants
Primary outcome timeframe
Median follow up times: 1) 298 days (exp), 249 days (ref) 2) 995 days (exp), 981 days (ref) 3) 515 days (exp), 448 days (ref) 4) 307 days (exp), 253 days (ref)
Results posted on
2025-11-10
Participant Flow
Participant milestones
| Measure |
Propranolol or Carvedilol
Exposure group
Propranolol or Carvedilol: Propranolol or Carvedilol claim is used as the exposure group.
|
Atenolol, Bisoprolol or Sotalol
Reference group
Atenolol, Bisoprolol or Sotalol: Atenolol, Bisoprolol or Sotalol claim is used as the reference group.
|
|---|---|---|
|
Overall Study
STARTED
|
583870
|
233467
|
|
Overall Study
COMPLETED
|
222015
|
222015
|
|
Overall Study
NOT COMPLETED
|
361855
|
11452
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Propranolol/Carvedilol Versus Atenolol/Bisoprolol/Sotalol
Baseline characteristics by cohort
| Measure |
Propranolol or Carvedilol
n=222015 Participants
Exposure group
Propranolol or Carvedilol: Propranolol or Carvedilol claim is used as the exposure group.
|
Atenolol, Bisoprolol or Sotalol
n=222015 Participants
Reference group
Atenolol, Bisoprolol or Sotalol: Atenolol, Bisoprolol or Sotalol claim is used as the reference group.
|
Total
n=444030 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
0 Participants
n=5 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
|
Age, Categorical
>=65 years
|
222015 Participants
n=5 Participants
|
222015 Participants
n=20 Participants
|
444030 Participants
n=40 Participants
|
|
Age, Continuous
|
74.77 years
STANDARD_DEVIATION 6.82 • n=5 Participants
|
74.75 years
STANDARD_DEVIATION 6.78 • n=20 Participants
|
74.77 years
STANDARD_DEVIATION 6.80 • n=40 Participants
|
|
Sex: Female, Male
Female
|
128266 Participants
n=5 Participants
|
127873 Participants
n=20 Participants
|
256139 Participants
n=40 Participants
|
|
Sex: Female, Male
Male
|
93749 Participants
n=5 Participants
|
94142 Participants
n=20 Participants
|
187891 Participants
n=40 Participants
|
|
Race/Ethnicity, Customized
White
|
177198 Participants
n=5 Participants
|
176941 Participants
n=20 Participants
|
354139 Participants
n=40 Participants
|
|
Race/Ethnicity, Customized
Black
|
22448 Participants
n=5 Participants
|
22557 Participants
n=20 Participants
|
45005 Participants
n=40 Participants
|
|
Race/Ethnicity, Customized
Hispanic
|
7289 Participants
n=5 Participants
|
7209 Participants
n=20 Participants
|
14498 Participants
n=40 Participants
|
|
Race/Ethnicity, Customized
Asian
|
7954 Participants
n=5 Participants
|
8042 Participants
n=20 Participants
|
15996 Participants
n=40 Participants
|
|
Race/Ethnicity, Customized
North American Native
|
1347 Participants
n=5 Participants
|
1426 Participants
n=20 Participants
|
2773 Participants
n=40 Participants
|
|
Race/Ethnicity, Customized
Other
|
4242 Participants
n=5 Participants
|
4273 Participants
n=20 Participants
|
8515 Participants
n=40 Participants
|
|
Race/Ethnicity, Customized
Unknown
|
1537 Participants
n=5 Participants
|
1567 Participants
n=20 Participants
|
3104 Participants
n=40 Participants
|
|
Dementia risk factors
Anxiety
|
32757 Participants
n=5 Participants
|
32295 Participants
n=20 Participants
|
65052 Participants
n=40 Participants
|
|
Dementia risk factors
Bipolar Disorder
|
2299 Participants
n=5 Participants
|
2263 Participants
n=20 Participants
|
4562 Participants
n=40 Participants
|
|
Dementia risk factors
Coronary artery disease
|
96483 Participants
n=5 Participants
|
96613 Participants
n=20 Participants
|
193096 Participants
n=40 Participants
|
|
Dementia risk factors
Depression
|
32918 Participants
n=5 Participants
|
32329 Participants
n=20 Participants
|
65247 Participants
n=40 Participants
|
|
Dementia risk factors
Diabetes
|
168274 Participants
n=5 Participants
|
168200 Participants
n=20 Participants
|
336474 Participants
n=40 Participants
|
|
Dementia risk factors
Obesity
|
48216 Participants
n=5 Participants
|
48375 Participants
n=20 Participants
|
96591 Participants
n=40 Participants
|
|
Dementia risk factors
Schizophrenia
|
1045 Participants
n=5 Participants
|
1064 Participants
n=20 Participants
|
2109 Participants
n=40 Participants
|
PRIMARY outcome
Timeframe: Median follow up times: 1) 298 days (exp), 249 days (ref) 2) 995 days (exp), 981 days (ref) 3) 515 days (exp), 448 days (ref) 4) 307 days (exp), 253 days (ref)Population: Study cohort after 1:1 propensity score matching
Time to dementia onset, i.e., Alzheimer's disease, vascular dementia, senile, presenile, or unspecified dementia, or dementia in other diseases classified elsewhere. Please refer to uploaded protocol for full definition due to size limitations.
Outcome measures
| Measure |
Propranolol or Carvedilol
n=222015 Participants
Exposure group
Propranolol or Carvedilol: Propranolol or Carvedilol claim is used as the exposure group.
|
Atenolol, Bisoprolol or Sotalol
n=222015 Participants
Reference group
Atenolol, Bisoprolol or Sotalol: Atenolol, Bisoprolol or Sotalol claim is used as the reference group.
|
|---|---|---|
|
Time to Dementia Onset
Analysis 1
|
22.96 Incidence rate per 1000 person year
Interval 22.48 to 23.45
|
19.84 Incidence rate per 1000 person year
Interval 19.35 to 20.33
|
|
Time to Dementia Onset
Analysis 2
|
26.82 Incidence rate per 1000 person year
Interval 26.22 to 27.44
|
25.84 Incidence rate per 1000 person year
Interval 25.25 to 26.45
|
|
Time to Dementia Onset
Analysis 3
|
23.03 Incidence rate per 1000 person year
Interval 22.47 to 23.6
|
20.21 Incidence rate per 1000 person year
Interval 19.64 to 20.79
|
|
Time to Dementia Onset
Analysis 4
|
7.21 Incidence rate per 1000 person year
Interval 6.95 to 7.49
|
6.47 Incidence rate per 1000 person year
Interval 6.2 to 6.75
|
Adverse Events
Propranolol or Carvedilol
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Atenolol, Bisoprolol or Sotalol
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: OTHER